A Phase 1 Study with Point-of-Care Manufacturing of Dual Targeted, Tandem Anti-CD19, Anti-CD20 Chimeric Antigen Receptor Modified T (CART-T) Cells for Relapsed, Refractory, Non-Hodgkin Lymphoma

被引：25
|
作者：
Shah, Nirav N. [1 ]
Zhu, Fenlu [2 ]
Taylor, Carolyn [2 ]
Schneider, Dina [3 ]
Krueger, Winfried [3 ]
Worden, Andrew [3 ]
Yim, Sharon [2 ]
Fenske, Timothy S. [1 ]
Hamadani, Mehdi [1 ]
Johnson, Bryon [4 ]
Dropulic, Boro [5 ]
Orentas, Rimas [3 ]
Hari, Parameswaran [6 ]
机构：
[1] Med Coll Wisconsin, Div Hematol & Oncol, Milwaukee, WI 53226 USA
[2] Med Coll Wisconsin, Milwaukee, WI 53226 USA
[3] Lentigen Technol Inc, Gaithersburg, MD USA
[4] Med Coll Wisconsin, Dept Med, Milwaukee, WI 53226 USA
[5] Lentigen, Gaithersburg, MD USA
[6] Med Coll Wisconsin, Dept Med, Menomonee Falls, WI USA
来源：
BLOOD | 2018年 / 132卷
关键词：
D O I：
10.1182/blood-2018-99-110194
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
4193
引用
收藏
页数：3
相关论文
共 50 条
  • [1] Results of a phase I study of bispecific anti-CD19, anti-CD20 chimeric antigen receptor (CAR) modified T cells for relapsed, refractory, non-Hodgkin lymphoma.
    Shah, Nirav Niranjan
    Zhu, Fenlu
    Schneider, Dina
    Taylor, Carolyn
    Krueger, Winfried
    Worden, Andrew
    Longo, Walter L.
    Hamadani, Mehdi
    Fenske, Timothy
    Johnson, Bryon
    Dropulic, Boro
    Orentas, Rimas
    Hari, Parameswaran
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [2] Clinical Results of a First-in-Human Phase 1 Study of Point-of-Care Manufactured Bispecific Anti-CD19, Anti-CD20 Chimeric Antigen Receptor Modified T (CAR-20.19-T) Cells for Relapsed, Refractory, Non-Hodgkin Lymphoma (NHL)
    Shah, Nirav N.
    Zhu, Fenlu
    Keever-Taylor, Carolyn
    Schneider, Dina
    Kruger, Winfred
    Worden, Andrew
    Hamadani, Mehdi
    Fenske, Timothy S.
    Johnson, Bryon D.
    Dropulic, Boro
    Orentas, Rimas
    Hari, Parameswaran
    BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2019, 25 (03)
  • [3] Clinical results of a first-in-human phase 1 study Bispecific anti-CD19, ANTI-CD20 chimeric antigen receptor modified (LV20.19CAR) T cells for relapsed, refractory, non-Hodgkin lymphoma
    Shah, Nirav
    Zhu, Fenlu
    Keever-taylor, Carolyn
    Schneider, Dina
    Kruger, Winfried
    Worden, Andrew
    Hamadani, Mehdi
    Fenske, Timothy
    Johnson, Bryon
    Dropulic, Boro
    Orentas, Rimas
    Hari, Parameswaran
    BONE MARROW TRANSPLANTATION, 2019, 54 : 123 - 124
  • [4] Point-of-care anti-CD19 chimeric antigen receptor T-cell therapy for relapsed/refractory follicular lymphoma
    Fried, Shalev
    Shkury, Eden
    Itzhaki, Orit
    Sdayoor, Inbal
    Yerushalmi, Ronit
    Shem-Tov, Noga
    Danylesko, Ivetta
    Jacoby, Elad
    Shouval, Roni
    Kedmi, Meirav
    Marcus, Ronit
    Nagler, Arnon
    Shimoni, Avichai
    Avigdor, Abraham
    LEUKEMIA & LYMPHOMA, 2023, 64 (12) : 1956 - 1963
  • [5] Sequential anti-CD19, anti-CD22, and anti-CD20 autologous chimeric antigen receptor T cell (CAR-T) therapies treating a child with relapsed refractory Burkitt lymphoma
    Du, Juan
    Zhang, Yonghong
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2019, 7
  • [6] Anti-CD19 Chimeric Antigen Receptor T Cells in Combination With Nivolumab Are Safe and Effective Against Relapsed/Refractory B-Cell Non-hodgkin Lymphoma
    Cao, Yaqing
    Lu, Wenyi
    Sun, Rui
    Jin, Xin
    Cheng, Lin
    He, Xiaoyuan
    Wang, Luqiao
    Yuan, Ting
    Lyu, Cuicui
    Zhao, Mingfeng
    FRONTIERS IN ONCOLOGY, 2019, 9
  • [7] Incorporating radiation with anti-CD19 chimeric antigen receptor T-cell therapy for relapsed/refractory non-Hodgkin lymphoma: A multicenter consensus approach
    Saifi, Omran
    Lester, Scott
    Breen, William
    Rule, William
    Lin, Yi
    Bennani, N. Nora
    Rosenthal, Allison
    Munoz, Javier
    Murthy, Hemant
    Kharfan-Dabaja, Mohamed
    Peterson, Jennifer
    Hoppe, Bradford
    AMERICAN JOURNAL OF HEMATOLOGY, 2024, 99 (01) : 124 - 134
  • [8] Phase I Trial of Fourth-Generation Anti-CD19 Chimeric Antigen Receptor T Cells Against Relapsed or Refractory B Cell Non-Hodgkin Lymphomas
    Zhou, Xuan
    Tu, Sanfang
    Wang, Chunsheng
    Huang, Rui
    Deng, Lan
    Song, Chaoyang
    Yue, Chunyan
    He, Yanjie
    Yang, Jilong
    Liang, Zhao
    Wu, Anqin
    Li, Meifang
    Zhou, Weijun
    Du, Jingwen
    Guo, Zhenling
    Li, Yongqian
    Jiao, Cheng
    Liu, Yuchen
    Chang, Lung-Ji
    Li, Yuhua
    FRONTIERS IN IMMUNOLOGY, 2020, 11
  • [9] Fresh Versus Cryopreserved/Thawed Bispecific Anti-CD19/CD20 CAR-T Cells for Relapsed, Refractory Non-Hodgkin Lymphoma
    Shah, Nirav N.
    Zhu, Fenlu
    Schneider, Dina
    Krueger, Winfried
    Worden, Andrew
    Longo, Walter L.
    Hamadani, Mehdi
    Fenske, Timothy S.
    Dropulic, Boro
    Orentas, Rimas J.
    Hari, Parameswaran
    Johnson, Bryon
    BLOOD, 2019, 134
  • [10] Phase 1 trial of CD19/CD20 bispecific chimeric antigen receptor-engineered naive/memory T cells for relapsed or refractory non-Hodgkin lymphoma
    Puliafito, Benjamin R.
    Walthers, Christopher
    Ji, Brenda
    Ghafouri, Sanaz N.
    Naparstek, Jacob
    Trent, Jacqueline
    Chen, Jia M.
    Roshandell, Mobina
    Harris, Caitlin
    Khericha, Mobina
    Schweppe, Thomas
    Berent-Maoz, Beata
    Gosliner, Stanley B.
    Almaktari, Amr
    Ceja, Melanie Ayala
    Allen-Auerbach, Martin S.
    Said, Jonathan
    Nawaly, Karla
    Mead, Monica
    de Vos, Sven
    Young, Patricia A.
    Oliai, Caspian
    Schiller, Gary J.
    Timmerman, John M.
    Ribas, Antoni
    Chen, Yvonne Y.
    Larson, Sarah M.
    CANCER RESEARCH, 2023, 83 (08)
12345